Cantel Medical Corp

Cantel Medical — Investor Presentation (March 2019)

34 slides from Cantel Medical's investor presentation, Mar 22, 2019

  1. Slide 1: Cantel Investor Presentation 3Q19

    CANTEL Investor Presentation 3Q19

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement This presentation may contain “forward-looking statements” as that term is defined under the Private Securities Litigation Reform Act of 1995 and other securities laws. For these statements, we claim the protection of the safe harbor for forward-looking statements contained

  3. Slide 3: Our Mission, Business Priorities and Values

    OUR MISSION Deliver innovative infection prevention solutions which improve outcomes and help save lives. OUR BUSINESS PRIORITIES Market Strategic Continuous Financial New Products Expansion Acquisitions Improvement Performance Continually introduce Expand our products Effectively identify, Continuo

  4. Slide 4: Sources of Strength

    Sources of Strength Leading pure-play in Government / industry the growing $50B focus on infection prevention is a growth global infection driver, shielding our 10%+ prevention market markets from with existing businesses in annual growth weak economic addressable markets of achieved over cycles ~$7

  5. Slide 5: Global Presence

    Global Presence 2,800+ Global Team members AUSTRALIA BELGIUM CANADA CHINA FRANCE GERMANY HONG KONG ITALY MALAYSIA NETHERLANDS UNITED ARAB EMIRATES (1) UNITED KINGDOM LTM Revenue UNITED STATES SINGAPORE 5 Cantel Medical Facilities / (1) Ended January 31, 2019

  6. Slide 6: Financial Performance – Track Record of Success

    Financial Performance – Track Record of Success 10+ Years of Growth and Margin Expansion $900 CAGR: ’03-’18 $800 $700 16% $600 $500 $400 $ in millions$in $300 $200 $100 20% $0 FY03 FY04 FY05 FY06 FY07 FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 1,2 2,3 Net Sales Adj. EBITDAS Net Debt / (C

  7. Slide 7: IP&C Markets We Serve

    IP&C Markets We Serve Our commitment is addressing critical infection prevention challenges globally 1 $501M1 $212M1 $151M MEDICAL LIFE SCIENCES DENTAL AND ALTERNATE CARE Endoscopy Reprocessing & Life Sciences, Water Purification & Dental, Hospital & Sterility Assurance Procedure Room Products Filte

  8. Slide 8: Long-Term Growth Drivers: Medical

    Long-Term Growth Drivers: Medical MARKET SIZE AND INDUSTRY DRIVERS THE CANTEL DIFFERENCE GROWTH Large and growing global • Focus on single-use products • Only pure-play infection addressable market totaling to decrease cross- prevention provider over $4.5 billion contamination • Full-circle product

  9. Slide 9: Long-Term Growth Drivers: Life Sciences

    Long-Term Growth Drivers: Life Sciences MARKET SIZE AND INDUSTRY DRIVERS THE CANTEL DIFFERENCE GROWTH • US ESRD patient • ~6,5001 dialysis clinics in • Leading hemodialysis water population growing at 3-4% U.S. filtration technology annually1 • Market adoption of heat- • Extensive network of Service

  10. Slide 10: Long-Term Growth Drivers: Dental

    Long-Term Growth Drivers: Dental MARKET SIZE AND INDUSTRY DRIVERS THE CANTEL DIFFERENCE GROWTH • ~ 198,000 dentists in the • Infection prevention remains • Leading dental brand for US(1) a headline risk for dental infection prevention • 213 million annual2 US dental practitioners globally • High mar

  11. Slide 11: Growth Strategy

    Growth Strategy Achieve global IP leadership by executing our business priorities Global Market Strategic Expansion Acquisitions New Products Operating Model Commercial Excellence | Team Development | Infrastructure | Continuous Improvement 11

  12. Slide 12: Market Expansion: Significant Global Investment in Sales & Marketing

    Market Expansion: Significant Global Investment in Sales & Marketing Substantial Growth • Medical team doubled in the last 3 years of US Direct Sales with proven Commercial Excellence model Team • Life Sciences and Dental teams expanding International • Accelerating investments • Go-direct in 15 cou

  13. Slide 13: Strategic Acquisitions

    Strategic Acquisitions: Proven ability to integrate, leverage and grow acquisitions Medical Dental Life Sciences International • Aexis Medical, BHT • Omnia S.p.A., SPS • Stericycle’s CES • Belgium: Aexis Medical business. NAMSA’s Group, Byrne Medical, Medical, DentaPure,, • Germany: BHT Group PuriCo

  14. Slide 14: New Products: Global R&D process driving new product development

    New Products: Global R&D process driving new product development Medical Life Sciences Dental • Advantage Plus® Pass- • REVOX® Sterilization • Sanitex Plus™ 2 Thru Solutions Surface Disinfectant • Scope Buddy Plus® • EON™ Portable Water Spray • Full line of DEFENDO™ System • SafeFlo™ Saliva valves f

  15. Slide 15: The Cantel Operating Model

    The Cantel Operating Model is the Foundation to Enable Growth and Leverage Commercial Team Continuous Infrastructure Excellence Development Improvement Establish Attract, retain Deploy lean systems & Target sales and develop processes and procedures to growth above the best team improvement optimize

  16. Slide 16: NYSE Infection Prevention Leader

    $896M1 NYSE Infection Prevention Leader Recurring revenue Strong financial performance 36 for more than and $174.4M in LTM Successful 1,2,3 Adj. EBITDAS acquisitions 10 since 2000 YEARS 73% Total available market Sustainable double Excellent record with Strong core business 10x sales - Global Strong

  17. Slide 17: Thank You

    THANK YOU 21

  18. Slide 18: Appendix

    APPENDIX

  19. Slide 19: Strong Financial Performance with High Quality Earnings

    Strong Financial Performance with High Quality Earnings Last Twelve Months (LTM) Ended January 31, 2019 NET SALES: $896.2M OPERATING INCOME: $156.4M1 OPERATING INCOME MARGIN: 17.5%1 Total Revenue Growth = 8.8% Adjusted EBITDAS = $174.4M2,3 Organic Revenue Growth = 6.2% Adjusted EBITDAS Margin = 19.5

  20. Slide 20: Omnia S.p.A

    Omnia S.p.A February 1, 2019 Manufactures a wide ranging portfolio of single-use dental surgical consumables with focus on procedure room set-up and cross contamination prevention Purchase price of $31.9M in cash and stock consideration For the trailing twelve months ending July 31, 2018, Omnia S.p.

  21. Slide 21: Vista Research Group

    Vista Research Group January 11, 2019 Manufactures a portfolio of products that simplifies how purified water for dental clinics are sourced and steri-waste water is disposed of Purchase price of $10.5M in cash and stock consideration For the trailing twelve months ending December 31, 2018, Vista Re

  22. Slide 22: Stericycle's Controlled Environmental Solutions

    Stericycle’s Controlled Environmental Solutions August 3, 2018 Leading provider of testing and certification, environmental monitoring and decontamination services for clean rooms and other controlled environments Purchase price of $17.0M in cash consideration For the trailing twelve months ending D

  23. Slide 23: Aexis Medical

    Aexis Medical March 21, 2018 Specializing in advanced software solutions focused on the tracking and monitoring of instrument reprocessing workflows for hospitals and healthcare professionals Purchase price of $24.8M, $21.1M in cash consideration and $3.7M in an earnout structure to be paid at the t

  24. Slide 24: BHT Group

    BHT Group August 23, 2018 German leader in automated endoscope reprocessing, endoscope storage and drying cabinets, washer-disinfectors for central sterile applications and flexible endoscope repair Purchase price of $60.8M in cash consideration For the trailing twelve months ending May 31, 2017, BH

  25. Slide 25: Historical P&L Reveals Success of Growth Programs

    Historical P&L Reveals Success of Growth Programs Fiscal Year Ending 7/31/2018 ($ in millions, CAGR: except per share data) FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 ’11 -’18 Net Sales $321.7 $386.5 $425.0 $488.7 $565.0 $665.0 $770.2 $871.9 15% Gross Profit $122.8 $164.2 $183.5 $213.3 $253.5 $309.2 $3

  26. Slide 26: Strong Balance Sheet & Cash Flow Generation

    Strong Balance Sheet & Cash Flow Generation Fiscal Year 2018 Ending 7/31/2018 ($ and shares in millions) FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 Total Assets $279.2 $277.9 $280.7 $321.4 $434.8 $487.7 $536.1 $584.0 $694.5 $786.4 $963.7 Current Ratio 2.2:1 2.3:1 2.3:1 2.6:1 2.4:1 2.5:1

  27. Slide 27: GAAP to Non-GAAP EPS Reconciliation

    GAAP to Non-GAAP EPS Reconciliation Fiscal Year 2018 Ending 7/31/2018 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 GAAP Diluted EPS1 $0.52 $0.77 $0.95 $1.04 $1.15 $1.44 $1.71 $2.18 + Intangible amortization $0.10 $0.14 $0.16 $0.16 $0.21 $0.22 $0.30 $0.32 + Acquisition related items $0.02 ($0.02) ($0.02)

  28. Slide 28: Income to Adjusted EBITDAS Reconciliation

    Income to Adjusted EBITDAS Reconciliation Fiscal Year 2018 Ending 7/31/2018 ($ in millions) FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 Net Income $8.7 $15.6 $19.9 $20.4 $31.3 $39.2 $43.3 $48.0 $60.0 $71.4 $91.0 + Income taxes 5.2 9.4 11.6 10.0 16.5 21.1 25.3 28.2 34.0 34.9 26.5 + Net Int

  29. Slide 29: Gross Debt to Net Debt Reconciliation

    Gross Debt to Net Debt Reconciliation Fiscal Year 2018 Ending 7/31/2018 ($ in millions) FY08 FY09 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 FY18 Gross Debt $58.3 $43.3 $21.0 $122.0 $90.0 $95.0 $80.5 $78.5 $116.0 $126.0 $200.0 - Cash (18.3) (23.4) (22.6) (18.4) (30.2) (34.1) (31.8) (31.7) (28.4) (36.6)

  30. Slide 30: GAAP to Non-GAAP EPS Disclosure

    GAAP to Non-GAAP EPS Disclosure Non-GAAP financial measures contained herein supplement information previously reported in filings on Form 10-Q and Form 10-K as well as in presentations by Company management to investors, analysts and others. The information below will not be deemed “filed” for purp

  31. Slide 31: GAAP to Non-GAAP EPS Disclosure (continued)

    GAAP to Non-GAAP EPS Disclosure (continued) (b) Non-GAAP Gross Profit Rate We define non-GAAP gross profit rate, adjusted to exclude acquisition related items as management deems these items to be irregular or non-operating in nature. For the three months ended July 31, 2018 we made adjustments to N

  32. Slide 32: GAAP to Non-GAAP EPS Disclosure (continued)

    GAAP to Non-GAAP EPS Disclosure (continued) (d) Non-GAAP Net Income and Non-GAAP Diluted EPS We define non-GAAP net income and non-GAAP diluted EPS as net income and diluted EPS, respectively, adjusted to exclude (i) amortization of purchased intangible assets; (ii) acquisition-related items; (iii)

  33. Slide 33: GAAP to Non-GAAP EPS Disclosure (continued)

    GAAP to Non-GAAP EPS Disclosure (continued) Amortization Expense of Purchased Intangible Assets Amortization expense of purchased intangible assets is a non-cash expense related to intangibles that were primarily the result of business acquisitions. Our history of acquiring businesses has resulted i

  34. Slide 34: GAAP to Non-GAAP EPS Disclosure (continued)

    GAAP to Non-GAAP EPS Disclosure (continued) U.S. Income Tax Reform The 2017 Tax Act significantly revised U.S. tax law by, among other provisions, (a) lowering the applicable U.S. federal statutory income tax rate from 35% to 21%, (b) creating a partial territorial tax system that includes imposing

Cantel Medical — Investor Presentation (March 2019) on 6ix